Sight Sciences, Inc. (NASDAQ:SGHT) COO sells $20,690.24 worth of stock

Vaseline1 week ago

0 3 minutes read

Sight Sciences, Inc. (NASDAQ:SGHT – Get Your Free Report ) COO Sam Boong Park sold 3,403 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $6.08, for a total value of $20,690.24. Following the completion of the sale, the chief operating officer now owns 254,826 shares of the company’s stock, valued at approximately $1,549,342.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible via this hyperlink.

Sight Sciences trading down 2.9%

Shares of NASDAQ SGHT traded down $0.18 during trading hours on Thursday, reaching $6.00. 149,380 shares of the company traded hands, compared to its average volume of 197,109. The stock has a market cap of $298.54 million, a price-to-earnings ratio of -5.36 and a beta of 2.71. The company has a current ratio of 11.01, a quick ratio of 10.50, and a debt-to-equity ratio of 0.33. The company’s 50-day moving average price is $6.54 and its 200-day moving average price is $6.23. Sight Sciences, Inc. it has a 12-month low of $1.04 and a 12-month high of $8.45.

Sight Sciences (NASDAQ:SGHT – Get Your Free Report ) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.06. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.90%. The company had revenue of $21.37 million for the quarter, compared to the consensus estimate of $21.32 million. In the same quarter last year, the company posted EPS of ($0.30). On average, equities research analysts anticipate that Sight Sciences, Inc. will record -1 earnings per share for the current fiscal year.

Changes in Analyst Ratings

Want more great investment ideas?

SGHT has been the subject of several recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a report on Friday, August 2nd. Lake Street Capital initiated coverage on Sight Sciences in a report on Wednesday, August 21st. They set a “buy” rating and a $10.00 price target for the company. Citigroup lifted their price objective on Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a report on Wednesday, July 10th. Finally, Morgan Stanley lifted their price objective on Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $7.25, according to MarketBeat.com.

Check out our latest analysis on SGHT

Institutional investors weigh in on the sciences

A number of hedge funds have recently made changes to their positions in the stock. Steele Capital Management Inc. purchased a new stake in Sight Sciences in the second quarter valued at about $67,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Sight Sciences in the first quarter valued at approximately $59,000. SG Americas Securities LLC purchased a new stake in Sight Sciences in the third quarter valued at about $75,000. The Manufacturers Life Insurance Company acquired a new stake in Sight Sciences in the second quarter valued at approximately $95,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Sight Sciences by 51.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock worth $141,000 after acquiring an additional 9,106 shares during the period. 55.51% of the shares are currently held by hedge funds and other institutional investors.

About Vision Sciences

(Get a free report)

Sight Sciences, Inc, an ophthalmic medical device company, is engaged in the development and commercialization of surgical and non-surgical technologies for the treatment of eye diseases. It operates through two segments, surgical glaucoma and dry eye. The company’s products include the OMNI Surgical System, an implant-free glaucoma surgical technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and the SION Surgical Instrument, a hand-operated device used in ophthalmic surgical procedures for excision of the trabecular meshwork.